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Abstract
Psychostimulant medications, such as Methylphenidate 
03+KDYHEHFRPHPDLQVWD\WUHDWPHQWVIRU$WWHQWLRQ'H¿FLW 
Hyperactivity Disorder (ADHD) symptoms, such as hyperactivity, 
impulsivity and inattention in children. Such symptoms frequently 
also co-exist in children with Autistic Spectrum Disorders (ASD), 
WKHUHE\FRPSOLFDWLQJDGL*甀eUHQWLDOGLDJQRVLV7KHSUHVHQFHRI
$'+'OLNHV\PSWRPVLQFKLOGUHQZLWK$6'FDQKDYHDVLJQL¿FDQW
detrimental impact on learning and social interaction, and can limit 
the outcome of behavioural interventions to address areas of core 
$6'GL*?FXOWLHV7KHUHIRUHLWLVRIFOLQLFDOUHOHYDQFHDQGSRWHQWLDO
EHQH¿WWRDGGUHVVWKHLVVXHRIH*甀eFWLYHQHVVDQGWROHUDELOLW\VDIHW\
of stimulants such as methylphenidate in children with co-morbid 
diagnoses of ASD + ADHD.
7KLV VWXG\ SHUIRUPHG D PHWDDQDO\VLV RI WKUHH UDQGRPLVHG 
FRQWUROOHGWULDOVKRPRJHQHRXVO\PHDVXULQJWKHH*甀eFWRILPPHGLDWH




question of medication use in this population.
Introduction
$WWHQWLRQ'H¿FLW+\SHUDFWLYLW\'LVRUGHU$'+'DQG$XWLVWLF 
Spectrum Disorders (ASDs) are both neurodevelopmental 
conditions with symptoms emerging in early childhood [1]. 




considering the clinical diagnostic descriptors of ADHD and ASD, 
there is little in common in terms of their presentation, however, 
in clinical practice children with ASD displaying concomitant 
³$'+'OLNH´EHKDYLRXUVDUHFRPPRQO\REVHUYHG>@,QGHHG
UHFHQWGDWDIURPD86VXUYH\RIWKHGLDJQRVLV	WUHDWPHQW
of ADHD showed that one in eight children with ADHD also had 
a concomitant diagnosis of ASD [7]. Section E of the diagnostic 
criteria for ADHD [8] does not allow a comorbid diagnosis of ASD 
and ADHD, though there are examples of ADHD being co-morbid 
with other frontostriatal disorders such as obsessive-compulsive 
GLVRUGHU	FRQGXFWGLVRUGHU>@7KHUDWLRQDOHKDVEHHQWKDW
symptoms of ADHD in ASD are attributable to an ASD diagnosis. 
:KLFKEURDFKHVWKHTXHVWLRQ³LVDGLDJQRVWLFFRPRUELGLW\RI$6'
DQG$'+'MXVWL¿HG"´&RPRUELGLW\FRXOGVLPSO\EHWKHUHVXOW
of the broad diagnostic description of both disorders. ADHD 
V\PSWRPVLQFKLOGUHQZLWK$6'DSSHDUVXSHU¿FLDOO\VLPLODUWR
$'+'V\PSWRPVLQFKLOGUHQZLWKRXW$6'DQGYLFHYHUVD>@
Based on the current diagnostic criteria an overlap exists making 
LWGL*?FXOWWRGLVWLQJXLVKWKHPEXWFDQRUVKRXOGWKHVHGLVRUGHUV
EHWUHDWHGVLPLODUO\">@
In order to address this, we must consider if the two disorders 
VKDUHDHWLRORJLFDODQGQHXURDQDWRPLFDOFRPPRQDOLWLHV"0DQ\
structural abnormalities have been found in the frontal lobe 
IRUERWK$6'>@DQG$'+'EXWQHXURLPDJLQJVWXGLHVRI 





cortex [17] and involve domains of planning and goal directed acts, 
SUREOHPVROYLQJDQGVWUDWHJ\GHYHORSPHQWÀH[LELOLW\SHUVLVWHQFH
1RU&DO2SHQ$FFHVV3XEOLFDWLRQV..  
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toward a goal state and self-awareness [18], with such functions 
being mediated through a network of neurons that interconnect 
RQGHQGULWLFVSLQHV7KH$6'EHKDYLRXUVSURSRVHGWREHUHODWHG




functions such as planning, working memory, and hyperactivity 
>@7KHOLWHUDWXUHKLJKOLJKWVWKHFRPSOH[QDWXUHRIH[HFXWLYH
function dysregulation in neurodevelopmental disorders and the 
fact that individual subtypes of the disorders have an impact upon 
presentation of symptoms.
Data from epidemiological twin and family studies have provided 
HYLGHQFHRIVWURQJJHQHWLFLQÀXHQFHVOLQNHGWRWKHGHYHORSPHQWRI
both ASD and ADHD. Both are neurodevelopmental disorders, with 
suggestions that ADHD results from a delay in brain maturation 
UDWKHUWKDQDFRPSOHWHGHYLDWLRQIURPW\SLFDOGHYHORSPHQW>@
7KHEUDLQPDWXUDWLRQK\SRWKHVLVWDNHVLWVHYLGHQFHIURPWKHIDFW







long-term safety of stimulant medication in children with ASD.
Standard drugs for treating ADHD are stimulant medications, 
such as Methylphenidate (MPH), and non-stimulants such as 
DWRPR[HWLQH>@7KH1DWLRQDO,QVWLWXWHRI&OLQLFDO([FHOOHQFH 
1,&('LDJQRVWLF	&OLQLFDO*XLGHOLQH&*IRU$'+'
states that stimulant medication should be considered as 
¿UVW OLQH WUHDWPHQW LQFRUSRUDWHG LQWRDFRPSUHKHQVLYHFDUH 




ZLWKKLJK D*?QLW\ WKHUHE\EORFNLQJ WKH LQZDUG WUDQVSRUW RI 
dopamine and prolonging the action of dopamine at its postsynaptic 
UHFHSWRUVLQWKHSUHIURQWDOFRUWH[>@03+D*甀eFWV'$WUDQVSRUW
LQGLUHFWO\YLDWKH9HVLFXODU0RQRDPLQH7UDQVSRUWHU90$7
located on intracellular vesicular membranes of monoaminergic 
neurones (which is known to remove cytoplasmic dopamine and 
noradrenaline into vesicles and control their storage and release) 
>@,WLVH[SHFWHGWKDWIROORZLQJDVLQJOHDGPLQLVWUDWLRQRI03+
a rapid and reversible increase in vesicular dopamine transport 
E\WKH90$7WDNHVSODFHSURPRWLQJUHPRYDORIGRSDPLQHLQWR
YHVLFOHVIRUIXWXUHUHOHDVH>@$XJPHQWDWLRQRIGRSDPLQHDQG
noradrenaline in the prefrontal cortex is believed to then ameliorate 
executive dysfunction.
From existing literature, it is clear there are some similarities, 
EXWDOVRPDMRUGL*甀eUHQFHVEHWZHHQ$'+'DQG$6'LQWHUPVRI
the diagnostic criteria, presentation of symptoms, brain changes, 
D*甀eFWHGQHXURWUDQVPLWWHUVDQGWUHDWPHQWVWUDWHJLHV7KHTXHVWLRQ
UHPDLQV,VLWRIFOLQLFDOEHQH¿WWRXVHVWLPXODQWPHGLFDWLRQLQ$6'
even though the neurotransmitters (Dopamine and Noradrenaline), 




there is still a lack of data, regarding its long-term safety in children 
ZLWK$'+'>@2QO\DIHZVWXGLHVKDYHFROOHFWHGH*?FDF\GDWD
on short term use of MPH on ADHD-like symptoms in children 
with a primary diagnosis of autism. It is the aim of this review 
DQGPHWDDQDO\VLVWRFODULI\WKHH*?FDF\RIWKHLPPHGLDWHUHOHDVH
preparation of methylphenidate to reduce hyperactivity in children 
ZLWKDXWLVWLFVSHFWUXPGLVRUGHU7KLVPD\KHOSLQIRUPWKHFOLQLFDO
DSSUHFLDWLRQRIWKHEHQH¿WVULVNUDWLRWKDWSKDUPDFRWKHUDS\PLJKW




review by searching several databases to identify relevant literature 
on the use of stimulant medication for treating ADHD-related 
V\PSWRPVLQFKLOGUHQZLWK$6'7KHVHDUFKIRFXVHGRQVWXGLHV 
that assessed the use of methylphenidate in children and 
DGROHVFHQWV\HDUVRIDJHDVLWLVWKH¿UVWOLQHPHGLFDWLRQ
for treating ADHD and ADHD symptoms in ASD within the 
8.LL7RH[WUDFWUHOHYDQWGDWDIURPUDQGRPL]HGFRQWUROVWXGLHV
in order to perform a meta-analysis to determine the scope of 
H*甀eFWLYHQHVVRIPHWK\OSKHQLGDWHWRFRQWUROSUREOHPDWLF$'+'OLNH 
EHKDYLRXUVLQFKLOGUHQDQGDGROHVFHQWVZLWK$6'LLL7RFRQGXFW
a concomitant appraisal of the tolerability of methylphenidate in 
this patient sub grouping.
A decision was made to concentrate this study only on the 
H*甀eFWLYHQHVVRILPPHGLDWHUHOHDVH03+DVWKLVFRPSULVHGWKH
greatest number of completely homogeneous studies which were 
amenable to comparison utilising the meta-analytical approach.
Inclusion criteria
7KLVUHYLHZLQYROYHVDQDQDO\VLVRIVWXGLHVWKDWIRFXVHGRQXVH
of MPH in treating ADHD related symptoms in children and 
DGROHVFHQWVZLWK$6'(DFKVWXG\WKDWPHWWKHSUHGH¿QHGLQFOXVLRQ 
FULWHULDZDVDQDO\VHGDQGVXPPDUL]HGZLWKLQ WKH IROORZLQJ 
categories: a) Methods used - specifying rating scales employed, b) 
$LPVRIWKHVWXG\LHDVVHVVPHQWRIH*?FDF\WROHUDELOLW\F'XUDWLRQ 
DQGVDPSOHVL]HG5HVXOWVH/LPLWDWLRQVDQGFRQFOXVLRQV 
7RDVVHVVWKHFHUWDLQW\RI WKHHYLGHQFHVWDWHGE\HDFKRI WKH 
selected studies, the studies were critically appraised, taking into 





























for the studies meeting the inclusion criteria were reviewed to 
identify any additional studies that also met the inclusion criteria.
$IROORZXSVHDUFKZDVFRQGXFWHGLQ0D\XWLOLVLQJWKHVDPH
VHDUFKFULWHULDZKLFKXQFRYHUHGIRXUDGGLWLRQDOVWXGLHV7KHVH
studies were of topic relevance, but could not be included in the 
PHWDDQDO\VLVIRUWKHUHDVRQVJLYHQLQWKHLQFOXVLRQ	H[FOXVLRQ
criteria section below.










presence of any other co-morbidity led to the study being excluded 




included in our analyses had only diagnoses of ASD + ADHD to 
allow as homogenous a set of participants as was feasible.
For ease of comparison, only studies utilising Immediate Release 
0HWK\OSKHQLGDWH,503+ZHUHLQFOXGHG7KLVZDVGHFLGHGVLQFH





methodology was not considered rigorous enough.
An additional four studies were found in the follow up literature 
VHDUFKFRQGXFWHGLQ7KHVHZHUHFRQVLGHUHGRILQWHUHVWIRU
V\QWKHVLVRI¿QGLQJVDQGKDYHEHHQLQFOXGHGLQWKHGLVFXVVLRQ






with extended release methylphenidate in subjects with ASD + 
ADHD. (Figure 1).
Figure 1: Flowchart depicting the strategic process utilised in the selection and exclusion of relevant research studies to be included 




Ghuman et al. [19]RUPP [32]Handen et al. [21]Quintana et al. [38] 
ZHHNVZHHNVZHHNVZHHNVDuration
abSample size








































in tabular format for comparison. Information on study design, 
VDPSOHVL]HVH[UDWLRDQGUHVHDUFKWRROXVHGWRDVVHVV$'+'
V\PSWRPVGRVHH*?FDF\DQGWROHUDELOLW\RI03+ZDVH[WUDFWHG















homogeneity of data and meant that the four studies selected were 




























ASD appear to be lower than those quoted for children with a sole 






Figure 2: Histogram showing the range of response to immediate release methylphenidate across the 
VWXGLHV7KHQXPEHURISDUWLFLSDQWVZKRZHUHFODVVHGDVUHVSRQGHUVGDUNJUH\EDUVDQGWKH
number of participants who discontinued treatment, (light grey bars) during the studies.

















Eicacy if IR-MPH on hyperactivity
7KUHHVWXGLHV4XLQWDQDHWDO>@5833>@+DQGHQHWDO>@
looked at mean baseline and post treatment with MPH rating on 
WKH$%&+\SHUDFWLYLW\6FDOH7KHVHUHVXOWVZHUHDOVRUHSUHVHQWHG 





daily), in order to achieve homogenisation of data
Table 2:6XPPDU\RIWKHPHDQUDWLQJVRQWKH$%&K\SHUDFWLYLW\VXEVFDOHIROORZLQJWUHDWPHQWZLWKSODFHERRU












 WR WKH6WDQGDUGLVHG0HDQ'L*甀eUHQFH 60'ZKLFK LV WKH 
average score of participants in the intervention group and the 
DYHUDJHRISDUWLFLSDQWVLQWKHFRQWUROJURXS7KHEODFNGLDPRQG
DWWKHERWWRPRIWKHJUDSKVKRZVWKHDYHUDJHH*甀eFWVL]HRIDOO
three studies. From the forest plot, all lines fall on the left-hand 
side of the graph indicating that the participants receiving the 










has been commonly observed leading to the use of stimulant 
PHGLFDWLRQLQFKLOGUHQZLWK$6'WRWDUJHWVXFKV\PSWRPV7KLV
VWXG\VHWRXWWRGHWHUPLQHWKHH*甀eFWLYHQHVVDQGVDIHW\RIVWLPXODQW
medication when employed in this select population. Initially a 




when used in children with ASD presenting with ADHD symptoms. 
:HVHWRXWWRSHUIRUPDPHWDDQDO\VLVXVLQJWKH5&7VIURPWKH



















quoted the evidence available on use of MPH in treatment of 
K\SHUDFWLYLW\DVSURPLVLQJ,WLVLPSRUWDQWWRQRWHWKDWRXU¿QGLQJV






blind to the doses administered but it is hard to rule out the 
VXEMHFWLYHHOHPHQWRIUDWLQJVFDOHVZKLFKPLJKWKDYHLQÀXHQFHG
the results. For the Quintana study, the ratings were carried out on 
one day a week only following a three-hour intensive simulated 
structured classroom session, this potentially did not allow enough 
WLPHIRUHQYLURQPHQWDODGDSWDWLRQVIRUWKHSDUWLFLSDQWV7KHUHLV




results as more study data become available.




Meta analysis of eicacy of IR-MPH on hyperactivity 
measure
:HXWLOLVHGWKH7HDFKHUUDWHGPHDQ$%&+\SHUDFWLYLW\VXE-




(www.meta-analysis.com) to compare the placebo versus IR-MPH 
H*甀eFWDQGWKHUHVXOWVDUHUHSUHVHQWHGDVDIRUHVWSORWLQ¿JXUH
(*甀eFWVL]HVIRUWKHPHDVXUHVLQHDFKVWXG\ZHUHH[SUHVVHGDV+HGJ-
ess g value. Hedgess g uses n-1 to calculate standard deviation 
and is considered accurate since it allows for an adjustment for 
VPDOOVDPSOHVL]H7KHVHH*甀eFWVL]HVZHUHFRPSXWHGE\WDNLQJWKH
PHDQRQWKH$%&IROORZLQJ03+PLQXVWKHPHDQRIWKHSODFHER
divided by the pooled standard deviations. Studies were weighed 
DFFRUGLQJWRWKHQXPEHURISDUWLFLSDQWVLQFOXGHG7KH¿[HGPRGHO
was used as the studies were almost functionally similar and the 
JRDORIWKHPHWDDQDO\VLVZDVWRFRPSXWHWKHFRPPRQH*甀eFWVL]H
IRUWKHLGHQWL¿HGVWXGLHV
participants of the studies included in this analysis were boys, 
ZLWKRQO\JLUOV7RWDOSRROHG1 7KLVW\SHRIJHQGHU
disparity in the prevalence of autism has been noted numerous 










characteristics and severity of the presentation of ASD may im-
SDFWXSRQSKDUPDFRORJLFDOWUHDWPHQWH*?FDF\DQGEHKDYLRXUDO














had compared response and safety of MPH in an ADHD only 
group in comparison to ASD combined with ADHD symptoms. 
$UHWURVSHFWLYHDQGSURVSHFWLYHVWXG\E\1,&(>@ZDVWKHRQO\
study that did a comparison of stimulant medication in children 









carried out over a short period of time, but two retrospective 





concluded that there was some improvement in the target 
symptoms of hyperactivity, impulsivity, disinhibition and 
LQDWWHQWLRQDQGVLGHH*甀eFWVZHUHQRWVXVWDLQHGWKURXJKRXWWUHDWPHQW
episodes. It remains unclear whether stimulant medications are 
EHQH¿FLDOLQWKHORQJWHUPVLQFHPRVWFOLQLFDOWULDOVDUHRIVKRUW
duration and do not include a maintenance data collection phase. 
,WLVTXLWHDODUPLQJWKDWHYHQIRU$'+'RQO\DQLQGLFDWLRQIRU
ZKLFKWKHUHKDVDIDUPRUHHVWDEOLVKHGXVHRIVWLPXODQWPHGLFDWLRQ
there is limited and inconsistent evidence for positive clinically 
UHOHYDQWORQJWHUPH*甀eFWVRIVWLPXODQWPHGLFDWLRQ/RQJWHUP
IROORZXSGDWDRIWKH07$VWXG\>@WKHELJJHVWVWXG\WRGDWH
on ADHD) failed to provide support for long term advantages of 
PHGLFDWLRQWUHDWPHQWDQGV\PSWRPFRQWURO>@'LVFRQWLQXDWLRQ




From the collective information that was evaluated in this study, 
WKHH*甀eFWLYHQHVVRI,503+LQWKHVKRUWWHUPLVSURPLVLQJ7KHVH
¿QGLQJVVKRXOGEHYLHZHGZLWKFDXWLRQDVWKH\DUHEDVHGRQ 
hyperactivity only. However more recent studies have indicated that 
other behaviours may be improved by methylphenidate treatment. 
6WXGLHV>@FRPSOHWHGDVHFRQGDU\DQDO\VLVRIWKH5833GDWD







LUULWDELOLW\ OHWKDUJ\DQGVWHUHRW\S\ LQDZHHN WULDO 1 
participants). Social behaviours were improved and aspects 
of impulsivity, inattention and oppositional behaviours were 
attenuated by extended release MPH in a further study conducted 
E\0F&UDFNHQHWDO >@7KHVHVWXGLHVFRXOGLQGLFDWH WKDW
VWLPXODQWWUHDWPHQWLQDW OHDVWDVXEJURXSRI\RXQJFKLOGUHQ
young people with ASD + ADHD could have more of a holistic 
EHQH¿FLDOH*甀eFW"
7KHDGYHUVHGUXJH*甀eFWVZKLFKDUHDSSDUHQWIURPWKLVVWXG\
are likely to be an unpredictable drawback in the use of MPH. 
7KHPRVWFRPPRQO\UHSRUWHGDGYHUVHH*甀eFWVRI03+LQ$6'




rochemical, genetic or behavioural underpinnings. From a 
EHKDYLRXUDOSHUVSHFWLYHVLGHH*甀eFWVDUHOLNHO\WREHSDUWLDOO\
due to the augmentation of problems already present in ASD as 
a result of treatment with MPH. Sleep disturbances are highly 
IUHTXHQWLQ$6'ZLWKSUHYDOHQFHUDWHVUDQJLQJIURP>@
they are multifactorial with a variety of mechanisms purported. 
Hypersensitivities to sound, light, certain textures or fabrics and 
abnormalities in melatonin release (amount or timing) may all 
FRQWULEXWHWRVOHHSGLVWXUEDQFHV>@03+LVNQRZQWRLQFUHDVH
H[WUDFHOOXODUOHYHOVRI'$E\GLVUXSWLQJWKHIXQFWLRQRI'$7
thus enhancing DA signalling in reward and motor pathways 
>@7KLVUHVXOWVLQSURPRWLRQRIDURXVDODQGSK\VLFDODFWLYLW\
further impeding sleep in children with ASD. Inadequate sleep 








habits and refuse many foods as they have a strong preference 
IRUVDPHQHVVLQFRORXUDQGWH[WXUH>@7KLVKDVEHHQOLQNHGWR
tactile and olfactory hypersensitivity which results in children 
ZLWK$6'KDYLQJGL*?FXOWLHVZLWKIRRGWH[WXUHVRUVPHOOV>@
Stimulant medications such as MPH are associated with a 
GHFUHDVHLQDSSHWLWH7KHFRPELQDWLRQRIDSSHWLWHGHFUHDVHVDQG
selective eating habits is likely to result in inadequate nutrition 
and reduction in caloric intake which in the long term will lead 
WRPRUHSURQRXQFHGJURZWKGH¿FLWVLQWKLVYXOQHUDEOHSRSXODWLRQ
$SKDUPDFRJHQHWLFVVWXG\FRQGXFWHGE\0DUFRHWDO>@LQWHUHVWLQJO\ 




















neurobiology and neurochemistry of ASD in order to enable 




IR-Methylphenidate stimulant medication in children with ASD 






study data on medication used to manage the aforementioned 
target symptoms becomes available. Safety of MPH appears to be 
DUHDOLVVXHDVDKLJKQXPEHURIDGYHUVHH*甀eFWVZHUHH[SHULHQFHG 
within the studies, which were severe enough to lead to 
frequent treatment discontinuation. It is interesting to consider if 
WKHUHLVDUHDQ\SDUWLFXODUFKDUDFWHULVWLFVRIWKH$6'SKHQRW\SH




Future investigations may shed light on what factors predict side 
H*甀eFWSUR¿OHLQWKLVSRSXODWLRQ,WPLJKWEHRIYDOXHWRHYDOXDWHWKH
e*甀eFWVRIVXEW\SHVZLWKLQ$6'DVUHVXOWVIURPWKHVWXG\E\&HU-
mak et al., [11] indicated that children with Aspergers disorder 





dose titration for each child must be considered alongside other 
FRQFHLYDEOHYDULDEOHVD*甀eFWLQJRYHUDOORXWFRPH7KHUHLVDOVR
a need to identify the clinical and biological variables that can 
predict which children would respond to treatment with stimulant 
medication and hence avoid exposure in those children who would 
RWKHUZLVHGHYHORSDGYHUVHH*甀eFWV
7KHUHLVDOVRDQHHGIRUORQJLWXGLQDOVWXGLHVWRDVVHVVWKHH*?FDF\RI




correlation between typical ASD symptoms and severity of adverse 
PHGLFDWLRQH*甀eFWVFRPPRQO\REVHUYHG
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